After retreating about 95% from its one-year highs to hit record lows for the year, Leafbuyer Technologies, Inc. (OTCQB:LBUY) is bouncing back. What is driving the stock and what could you expect from here?
LBUY continues to grow its sales at above industry average and the company now has a clear path to profitability. Moreover, Senator Bernie Sanders has outlined a plan that could significantly expand the market and funding opportunities for cannabis companies like LBUY. In this article, we take you through company-specific strengths and industry developments that could provide more upward lift to LBUY. But first, here’s a look at what LBUY does as a company.
LBUY bills itself as a leading cannabis marketing and technology company. LBUY, based in Colorado, operates a platform that serves both consumers and businesses. For consumers, the LBUY platform helps them find cannabis shops near them. For businesses, LBUY’s platform helps them market their products and build a loyal customer base.
Behind LBUY’s bounce back
The LBUY rebound comes on the company of the company providing a peek into its strength and potential as well as renewed efforts to expand America’s cannabis market.
- LBUY growing its sales at double-digit rate and above the industry average. LBUY’s cash sales for the quarter ending September 30, 2019 increased 27% compared to a similar period last year. That growth is higher than industry average of 24%. As sales surge, LBUY now sees a clear path to profitability. The company now aims to become profitable in the first half of 2020.
“While some of our competitors cut personnel, we successfully doubled our sales and support teams to manage the increased demand for our products and services,” commented Kurt Rossner, CEO of LBUY.
- Sanders sets cannabis legalization a priority. Senator Bernie Sanders is one of the leading candidates seeking Democratic presidential nomination. In fact, his popularity has surged in the latest poll. Sanders has seen the suffering of cannabis businesses and consumers and has made helping them a priority for his administration if he becomes president next year. Sanders last week (October 24) outlined a plan to legalize cannabis at the federal level. Although some 33 states have legalized cannabis, the substance remains prohibited under federal laws. However, Sanders plans to make cannabis legal at federal level within 3 months after taking the White House. Sanders will not wait for Congress to help him legalize cannabis. He plans to do it through executive action. Support for cannabis legalization has surged in the US.
Legalizing cannabis at federal level should expand both the market and financing opportunities for cannabis companies like LBUY. Presently, LBUY can only legal provide its services in 33 states. But federal legalization of cannabis would see LBUY’s market expand to all the 50 states. Moreover, big banks currently are afraid of doing business with cannabis companies, lest they run into trouble with federal regulators. However, legalizing cannabis at federal level should free the big banks to serve cannabis companies, and that could make access to credit easier for companies like LBUY.
LBUY stock catalysts
CBD.io acquisition to supercharge LBUY’s already soaring sales. LBUY is currently in talks to acquire Las Vegas-based trade show operation CBD.io. According to LBUY, CBD.io operates one of the largest and most visible cannabis expos. LBUY expects the acquisition of CBD.io to double its revenue.
LBUY wants to enter the big data game. LBUY looks to use its data resource to expand its business by entering the big data space. For example, LBUY wants to use the data it collects from visits to its platforms to help cannabis companies better understand the needs of their target customers. For LBUY, going to big data should help open a new revenue stream for the company.
The latest rebound in LBUY may just be the beginning of bigger things to come going by the company’s development plans we’ve examined and the growing support for federal cannabis legalization in the US. LBUY is one of those cannabis stocks with bright prospects that could deliver handsome results to investors. As LBUY makes the rounding bottom and turns higher, LBUY is one cannabis stock that needs to be on every pot stock investor’s radar.
We will be updating our subscribers as soon as we know more. For the latest updates on LBUY, sign up below!
Disclosure: We have no position in LBUY and have not been compensated for this article.
What Do Investors See In Medical Marijuana Stock (OTCMKTS:MJNA)?
Medical Marijuana Stock (OTCMKTS:MJNA) has emerged as one of many investor’s favorite pot stocks in the legal cannabis universe in 2020. The stock is already up about 10% in 2020, demonstrating how investors have warmed up to the stock early on in the New Year.
Following a disastrous 2019, cannabis investors lost money but have also learned that their best bets are stocks with strong fundamentals. They are looking for companies that have positioned themselves well in the cannabis industry and have what it takes to go for the opportunities. That is why MJNA stock is catching a lot of investor attention in 2020 because of how it has positioned itself in the cannabis market.
Robust revenue growth and strong financial position have also helped put MJNA on the radar of investors hunting for quality cannabis stocks. Revenue at MJNA more than doubled from $26.5 million in 2017 to $60 million in 2018. MJNA is also not in financial distress as may be the case with other cannabis companies out there. The company finished the third quarter, the most recent reported period, with $5.5 million in cash reserves.
Moreover, MJNA has recently taken steps to expand into new international markets and invest in companies that are leaders in their segments. These prudent actions are helping lift Medical Marijuana stock as more investors learn about them.
About Medical Marijuana stock
Is Tilray Inc (NASDAQ:TLRY) A Buy Or Sell?
For Tilray Inc (NASDAQ:TLRY) and the rest of cannabis stocks, 2019 was no doubt a bad year. But 2020 is shaping up to be a promising year for the stock. To start with, Tilray stock has already gained 8.35% year-to-date. If that says anything, it shows following the broad selloff in Tilray stock last year, we’ve got to a point where sellers are giving way to buyers in the stock.
There are several catalysts that should continue driving NASDAQ:TLRY as you’re about to see. First, below is a brief profile of the company we’re discussing.
Tilray is a Canada-headquartered global cannabis company. It is engaged in activities of cannabis cultivation and processing as well as marketing and distribution of cannabis products. Tilray already has several cannabis products brands to its portfolio. It operates across five continents through subsidiaries in Canada, Australia, Germany, and Portugal.
Following the broad collapse of cannabis stocks in 2019, investors are looking for cannabis stocks that can make a positive impact on their portfolios in 2020. Tilray stands out as an attractive cannabis stock pick in 2020. Here are some of the exciting things about the company.
Tilray CEO sees a bright future for the cannabis industry
On January 25, Tilray CEO Brendan Kennedy spoke on Bloomberg. In that interview, Kennedy framed a rosy outlook for the…
Is Cronos Stock (TSE:CRON)(NASDAQ:CRON) A Buy?
Cronos Stock (TSE:CRON)(NASDAQ:CRON) stock fell 9.22% on January 24, marking its steepest decline so far in 2020. The stock plunge followed an important disclosure that you would only expect from a company that is trying to be straight and transparent with investors. Here’s what happened.
On January 22, after market close, Cronos made a regulatory filing detailing changes in its executive team. In that SEC filing, Cronos revealed that David Hsu and William Hilson have stepped down as its chief operating officer and chief commercial officer, respectively. Unfortunately, some investors read bad news in the executive exits and sold their shares in Cronos.
But a careful reading of the filing doesn’t seem to raise any red flags. Therefore, the big stock plunged points to investors panicking to the degree of responding to a mosquito bite with a missile.
There is no doubt that 2019 was a difficult year for cannabis stocks and Cronos Stock is no exception. But before the uncalled for reaction to Cronos’s regulatory filing, we had been at a point where sellers were starting to give way to buyers in Cronos stock. The stock has gained about 8.0% in the past one month. It had gained more than 13% year-to-date before the January 24 big selloff.
About Cronos Stock
Cronos Stock is a Canada-based global cannabis company. Cronos operates through subsidiaries and…